資料載入中.....
|
請使用永久網址來引用或連結此文件:
http://ir.cmu.edu.tw/ir/handle/310903500/30555
|
| 題名: | Stabilizing of cytokeratin in PLC/PRF/5 cells |
| 作者: | Su, B;Liu, YH;Pei, RJ;Yeh, CC;Yeh, KT;Lee, KY;Hsu, YH;Ho, CC;Lai, YS |
| 貢獻者: | 醫學院醫學系病理學科;China Med Coll, Dept Pathol, Sch Med, Taichung, Taiwan;China Med Coll Hosp, Dept Urol, Taichung, Taiwan;Changha Christian Hosp, Dept Pathol, Changhua, Taiwan;Jen Ai Hosp, Dept Pathol, Taichung, Taiwan;Tzu Chi Hosp, Dept Pathol, Hua Lien, Taiwan;China Med Coll, Dept Physiol, Sch Med, Taichung, Taiwan |
| 日期: | 1999 |
| 上傳時間: | 2010-09-24 14:57:38 (UTC+8) |
| 出版者: | P J D PUBLICATIONS LTD |
| 摘要: | The objectives of this study are to describe the inhibitory effect of 9,10-anthraquinone 2-carboxylic acid (AQCA) on IgE-mediated passive cutaneous anaphylaxis (PCA) reaction, and the pharmacokinetics of AQCA. Pharmacodynamic assessments were performed at 0.5, 1 and 2 mg/kg (i.v.) and 5, 10 and 20 mg/kg (p.o) dose levels. In separate groups, pharmacokinetics were assessed at 5 mg/kg (i.v.) and 5, 10, and 20 mg/kg (p.o.) dose levels. Intravenous and oral administration of AQCA inhibited the PCA reaction in rats in a dose-dependent manner. The PCA-inhibitory activity of AQCA (20 mg/kg) lasted more than 12 hrs after oral administration. The oral bio-availability decreased with increasing dosage, from 96% (5 mg/kg) to 81% (10 and 20 mg/kg). The absorption after oral administration was prolonged with T-max values ranging from 1 to 6 h; while t(1/2) (4.8 - 16 h) values appeared to be comparable. These results suggest that AQCA has a potent and long acting anti-PCA activity. It is likely to be therapeutically useful in the treatment of asthma. |
| 關聯: | RESEARCH COMMUNICATIONS IN MOLECULAR PATHOLOGY AND PHARMACOLOGY 105(1月2日):11-22 |
| 顯示於類別: | [醫學系] 期刊論文
|
在CMUR中所有的資料項目都受到原著作權保護.
|
